CDT Equity (NASDAQ:CDT) Stock Rating Upgraded by Wall Street Zen

CDT Equity (NASDAQ:CDT) was upgraded by equities researchers at Wall Street Zen from a “sell” rating to a “hold” rating in a note issued to investors on Saturday.

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of CDT Equity in a report on Wednesday, June 24th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat, the stock presently has an average rating of “Sell”.

CDT Equity Stock Performance

Shares of CDT stock opened at $1.69 on Friday. CDT Equity has a twelve month low of $1.62 and a twelve month high of $2,739.80. The stock has a fifty day simple moving average of $4.06 and a two-hundred day simple moving average of $52.53. The stock has a market capitalization of $1.33 million, a price-to-earnings ratio of -0.00 and a beta of 1.52.

CDT Equity (NASDAQ:CDT) last released its quarterly earnings data on Wednesday, August 12th. The company reported ($8.71) earnings per share for the quarter.

Institutional Investors Weigh In On CDT Equity

A hedge fund recently bought a new stake in CDT Equity stock. Great Lakes Advisors LLC purchased a new position in CDT Equity Inc. (NASDAQ:CDT) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 18,631 shares of the company’s stock, valued at approximately $991,000. Great Lakes Advisors LLC owned about 2.96% of CDT Equity at the end of the most recent quarter. Institutional investors own 3.29% of the company’s stock.

CDT Equity Company Profile

Conduit Pharmaceuticals Inc, a clinical-stage specialty biopharmaceutical company, develops pharmaceutical products that provides unmet medical needs in the areas of autoimmune diseases and idiopathic male infertility. Its pipeline includes AZD1656, which has completed Phase I trials for the treatment of type 2 diabetes, renal transplant, Hashimoto's thyroiditis and Grave's disease, uveitis, and preterm labor; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility.